Compound Evidence File
#EC-2026-0774
Andarine S4
Filed under Oral Tablets. The bureau holds 167 laboratory returns for this compound from 62 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
62 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 10.0 | 10.0 | 13 Nov 2025 | 12 May 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 15 May 2026 | 7 Aug 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Jan 2026 | 15 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 26 Feb 2026 | 22 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 25 Dec 2025 | 27 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Apr 2026 | 26 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Jun 2026 | 22 Jun 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Feb 2026 | 28 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 9.9 | 20 Nov 2025 | 20 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 3 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 5 Mar 2026 | 15 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 15 May 2026 | 24 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 12 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 9.9 | 9.9 | 10.0 | 2 Feb 2026 | 18 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 9.9 | 9.9 | 10.0 | 4 Feb 2026 | 2 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Feb 2026 | 10 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 9.9 | 18 May 2026 | 14 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Mar 2026 | 6 Mar 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 27 May 2026 | 8 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Apr 2026 | 25 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 25 Mar 2026 | 14 Jul 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 8.7 | 8.7 | 8.7 | 3 Jul 2025 | 3 Jul 2025 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 1 | 8.4 | 8.4 | 8.4 | 28 Mar 2025 | 28 Mar 2025 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 8.3 | 8.3 | 8.3 | 16 Mar 2025 | 16 Mar 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.2 | 7.3 | 9.3 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.2 | 7.1 | 9.3 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.1 | 6.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 8.1 | 8.1 | 8.1 | 9 Jun 2025 | 9 Jun 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 8.1 | 8.1 | 8.1 | 27 Feb 2025 | 27 Feb 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 8.1 | 8.1 | 8.1 | 17 Dec 2024 | 17 Dec 2024 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.0 | 7.0 | 9.0 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.0 | 6.6 | 8.8 | 21 May 2026 | 21 May 2026 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 7.9 | 7.9 | 7.9 | 20 Jun 2025 | 20 Jun 2025 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 7 | 7.8 | 4.6 | 9.9 | 24 Apr 2025 | 21 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 7.7 | 7.0 | 8.5 | 8 Jul 2025 | 26 Jan 2026 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 7.7 | 7.7 | 7.7 | 2 Jul 2025 | 2 Jul 2025 |
| Peptide WorldwideCASE #VI-2026-0217 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Apr 2025 | 2 Apr 2025 |
| Xingruida XDRCASE #VI-2026-0898 | X | 6 | 7.2 | 5.7 | 9.1 | 7 May 2025 | 20 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 3 | 7.2 | 6.0 | 8.4 | 21 May 2025 | 24 May 2026 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 7.2 | 7.2 | 7.2 | 8 Jul 2025 | 8 Jul 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 7.2 | 7.2 | 7.2 | 17 Dec 2024 | 17 Dec 2024 |
| Skye PeptidesCASE #VI-2026-0451 | X | 2 | 7.1 | 5.6 | 8.7 | 13 Jun 2025 | 23 May 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 7.1 | 7.1 | 7.1 | 3 Jul 2025 | 3 Jul 2025 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 3 | 7.0 | 6.7 | 7.1 | 7 May 2025 | 23 May 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 4 | 6.4 | 4.4 | 8.8 | 16 Mar 2025 | 24 May 2026 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 6.4 | 6.4 | 6.4 | 17 Dec 2024 | 17 Dec 2024 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 11 | 6.3 | 3.6 | 8.9 | 9 Jun 2025 | 24 May 2026 |
| Mai PeptideCASE #VI-2026-0769 | X | 2 | 6.3 | 5.3 | 7.3 | 11 Jun 2025 | 21 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 2 | 6.3 | 5.6 | 7.0 | 13 Jun 2025 | 25 May 2026 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 6.1 | 6.1 | 6.1 | 14 Jan 2025 | 14 Jan 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 5.4 | 5.4 | 5.4 | 25 Apr 2025 | 25 Apr 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 5.3 | 5.3 | 5.3 | 9 Jun 2025 | 9 Jun 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 4.9 | 4.9 | 4.9 | 11 Jun 2025 | 11 Jun 2025 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 4.7 | 4.7 | 4.7 | 2 Jul 2025 | 2 Jul 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 2 | 4.3 | 3.5 | 5.2 | 3 Jul 2025 | 21 May 2026 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 4.2 | 4.2 | 4.2 | 9 Jun 2025 | 9 Jun 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 4.2 | 4.2 | 4.2 | 17 Dec 2024 | 17 Dec 2024 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 3.9 | 3.9 | 3.9 | 13 Feb 2025 | 13 Feb 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 2.2 | 2.2 | 2.2 | 2 Apr 2025 | 2 Apr 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 11 Jun 2025 | 11 Jun 2025 |
Open any subject to view the batch-level evidence for Andarine S4 alone.